➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Merck
Express Scripts
Mallinckrodt
Colorcon

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 8,048,872

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 8,048,872
Title:Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs
Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
Inventor(s): Curd; John G. (Hillsborough, CA), Keana; John F. W. (Eugene, OR), Lalani; Alshad S. (Tarrytown, NY), Westberg; Paul B. (San Mateo, CA), Goodwin; Bradford (San Mateo, CA), Henner; W. David (Tucson, AZ)
Assignee: Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon (Eugene, OR) N/A (N/A)
Application Number:12/111,672
Patent Claims:see list of patent claims

Details for Patent 8,048,872

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 2019-02-28 ⤷  Free Forever Trial Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon (Eugene, OR) N/A (N/A) 2026-02-17 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 2017-06-22 ⤷  Free Forever Trial Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon (Eugene, OR) N/A (N/A) 2026-02-17 RX Orphan search
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 2018-04-09 ⤷  Free Forever Trial Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon (Eugene, OR) N/A (N/A) 2026-02-17 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 2004-02-26 ⤷  Free Forever Trial Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon (Eugene, OR) N/A (N/A) 2026-02-17 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Mallinckrodt
Dow
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.